CD8A and neoplasm: To this end, we generated cytoplasmic ovalbumin‐expressing variants of these cell lines (B16‐cOVA and D5.1G4‐cOVA) so that we could evaluate OVA257‐specific CD8+ T cell (OT‐I) responses to a tumor‐specific Ag in the context of TFLN versus TILN.